Edition:
India

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

19.43USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$19.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
126,012
52-wk High
$31.23
52-wk Low
$8.10

Select another date:

Wed, Nov 15 2017

BRIEF-Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen

* Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS

BRIEF-Akcea Therapeutics Q3 loss per share $0.27

* Q3 earnings per share view $-0.19, revenue view $11.9 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-AKCEA PRESENTS DATA DEMONSTRATING SIGNIFICANT BURDEN OF ILLNESS IN FAMILIAL CHYLOMICRONEMIA SYNDROME

* AKCEA PRESENTS DATA DEMONSTRATING SIGNIFICANT BURDEN OF ILLNESS IN FAMILIAL CHYLOMICRONEMIA SYNDROME Source text for Eikon: Further company coverage:

BRIEF-Akcea and Ionis announce filing of new drug submission for Volanesorsen to Health Canada

* Akcea and Ionis announce filing of new drug submission for volanesorsen to Health Canada

BRIEF-Akcea Therapeutics establishes Canadian subsidiary

* Akcea Therapeutics Inc - Establishment of Ottawa-based Canadian unit and appointment of Jared Rhines as general manager for Akcea Therapeutics Canada Source text for Eikon: Further company coverage:

BRIEF-Akcea Therapeutics says co announced Mike Maclean joins as CFO, effective August 31

* Akcea Therapeutics says on Sept 5, co announced Mike Maclean joined company as Chief Financial Officer, effective August 31- SEC filing Source text for Eikon: [http://bit.ly/2eIZHLj] Further company coverage:

BRIEF-Akcea and Ionis submits New Drug Application for volanesorsen to FDA

* Akcea and Ionis announce submission of new drug application for volanesorsen to the U.S. FDA

BRIEF-Akcea Q2 loss per share $0.41

* Akcea reports financial results and highlights for second quarter 2017

BRIEF-Akcea, Ionis announce submission of marketing authorization application

* Akcea and Ionis announce submission of marketing authorization application for volanesorsen to the European Medicines Agency

BRIEF-Novartis reports 9.7 pct passive stake in Akcea Therapeutics as of July 19

* Novartis Pharma AG reports 9.7 percent passive stake in Akcea Therapeutics Inc as of July 19, 2017 - ‍​SEC filing Source text for Eikon: Further company coverage:

Select another date: